ASND
Price:
$139.7
Market Cap:
$8.03B
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.[Read more]
Industry
Biotechnology
IPO Date
2015-01-28
Stock Exchange
NASDAQ
Ticker
ASND
According to Ascendis Pharma A/S’s latest financial reports and current stock price. The company's current ROE is 212.63%. This represents a change of 239.34% compared to the average of 62.66% of the last 4 quarters.
The mean historical ROE of Ascendis Pharma A/S over the last ten years is -22.07%. The current 212.63% ROE has changed -1063.21% with respect to the historical average. Over the past ten years (40 quarters), ASND's ROE was at its highest in in the September 2023 quarter at 220.91%. The ROE was at its lowest in in the June 2023 quarter at -187.28%.
Average
-22.07%
Median
-41.10%
Minimum
-221.45%
Maximum
330.44%
Discovering the peaks and valleys of Ascendis Pharma A/S ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 410.16%
Maximum Annual ROE = 330.44%
Minimum Annual Increase = -249.22%
Minimum Annual ROE = -221.45%
Year | ROE | Change |
---|---|---|
2023 | 330.44% | -249.22% |
2022 | -221.45% | 410.16% |
2021 | -43.41% | -13.10% |
2020 | -49.95% | 36.81% |
2019 | -36.51% | -21.40% |
2018 | -46.45% | -29.81% |
2017 | -66.18% | 70.62% |
2016 | -38.79% | 41.77% |
2015 | -27.36% | 29.77% |
2014 | -21.08% | -132.57% |
The current ROE of Ascendis Pharma A/S (ASND) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
21.86%
5-year avg
-4.18%
10-year avg
-22.07%
Ascendis Pharma A/S’s ROE is greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than BeiGene, Ltd. (-25.12%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Blueprint Medicines Corporation (-47.66%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), less than United Therapeutics Corporation (19.22%), greater than IVERIC bio, Inc. (-39.26%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Chinook Therapeutics, Inc. (-41.23%), less than DICE Therapeutics, Inc. (56.07%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than 89bio, Inc. (-59.58%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than Arcellx, Inc. (-8.28%), greater than Stoke Therapeutics, Inc. (-54.45%),
Company | ROE | Market cap |
---|---|---|
-103.92% | $4.13B | |
-25.12% | $19.62B | |
-32.52% | $1.98B | |
-47.66% | $5.74B | |
-53.12% | $929.70M | |
-28.63% | $5.96B | |
-54.94% | $166.17M | |
19.22% | $16.23B | |
-39.26% | $5.51B | |
-85.39% | $278.99M | |
-25.23% | $12.60B | |
-22.40% | $1.28B | |
-41.23% | $2.71B | |
56.07% | $2.27B | |
-48.91% | $811.79M | |
-36.12% | $5.00B | |
-59.58% | $939.48M | |
-71.78% | $6.78B | |
-8.28% | $4.15B | |
-54.45% | $614.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ascendis Pharma A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ascendis Pharma A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Ascendis Pharma A/S's ROE?
How is the ROE calculated for Ascendis Pharma A/S (ASND)?
What is the highest ROE for Ascendis Pharma A/S (ASND)?
What is the 3-year average ROE for Ascendis Pharma A/S (ASND)?
What is the 5-year average ROE for Ascendis Pharma A/S (ASND)?
How does the current ROE for Ascendis Pharma A/S (ASND) compare to its historical average?